Journal article

ParkinSong: A Controlled Trial of Singing-Based Therapy for Parkinson's Disease

Jeanette Tamplin, Meg E Morris, Caterina Marigliani, Felicity A Baker, Adam P Vogel



Background. Communication impairment is one of the most common symptoms of Parkinson's disease (PD), significantly affecting quality of life. Singing shares many of the neural networks and structural mechanisms used during speech and, thus, has potential for therapeutic application to address speech disorders. Objective. To explore the effects of an interdisciplinary singing-based therapeutic intervention (ParkinSong) on voice and communication in people with PD. Methods. A controlled trial compared the effects of the ParkinSong intervention with an active control condition at 2 dosage levels (weekly vs monthly) over 3 months, on voice, speech, respiratory strength, and voice-related quality..

View full abstract


Awarded by Australian Research Council

Awarded by NHMRC

Funding Acknowledgements

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: JT is funded by the National Health and Medical Research Council (NHMRC) and Australian Research Council (Fellowship ID1106603) and The University of Melbourne. MEM is funded by NHMRC grants (APP1134495, APP1104237, APP1114210, APP11523) and has a joint appointment with Healthscope and La Trobe University. CM is employed by Parkinson's Victoria. FAB is funded by NHMRC grants (APP1169867, APP1137853) and is employed by The University of Melbourne. APV is chief science officer of Redenlab who provided assistance with the acoustic analysis. He receives salaried support from the NHRMC (Fellowship ID1152223) and also receives institutional support from The University of Melbourne. This research was funded by The University of Melbourne.